Skip to content
DataLookout
Menu

NCT05694715

Combination Therapy in Cancers With Mutations in DNA Repair Genes

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved 7 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 5 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Jan 31, 2028 to Aug 31, 2028 Show 4 more changesShow less
    • Eligibility criteria revised
    • Enrollment closed, study ongoing
    • Secondary endpoints: details revised at 3 of 4 entries
    • Site details revised
  2. Minor Site contact updatedv6
  3. Notable Eligibility criteria expanded, about 1 wordv3
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Dec 31, 2027 to Jan 31, 2028
    • Start date changed from estimate of Apr 1, 2023 to May 23, 2023
    • Site details revised
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage of participants with treatment-emergent adverse events
Timeframe: 30 days after the last dose
Maximum Tolerated Dose (MTD)
Timeframe: 30 days after the last dose
Percentage of participants with Dose Limiting Toxicities (DLTs)
Timeframe: 30 days after the last dose
Recommended Phase 2 Dose (RP2D)
Timeframe: Up to 2 years

Secondary (4)

Overall response rate (ORR)
Duration of overall response (DOR)
Median duration of stable disease (SD)
Median Progression-Free Survival (PFS)

Arms and interventions

Cohort 1 (Niraparib, Irinotecan)Experimental

Participants will receive a starting dose of 100 mg of niraparib on days 1-7 each 21-day cycle, and 100 mg/m\^2 of irinotecan on day 1 of each 21 day cycle until unacceptable toxicity, disease progression or participant withdrawal.

Cohort 2 (Niraparib, Irinotecan)Experimental

Participants will receive a starting dose of 200 mg of niraparib on days 1-7 each 21-day cycle, and 100 mg/m\^2 of irinotecan on day 1 of each 21 day cycle until unacceptable toxicity, disease progression or participant withdrawal.

Cohort 3a (Niraparib, Irinotecan)Experimental

Participants weighing \< 77 kg will receive a starting dose of 200 mg of niraparib on days 1-7 each 21-day cycle, and 100 mg/m\^2 of irinotecan on day 1 of each 21 day cycle until unacceptable toxicity, disease progression or participant withdrawal.

Cohort 3b (Niraparib, Irinotecan)Experimental

Participants weighing \>= 77 kg will receive a starting dose of 300 mg of niraparib on days 1-7 each 21-day cycle, and 100 mg/m\^2 of irinotecan on day 1 of each 21 day cycle until unacceptable toxicity, disease progression or participant withdrawal.

Cohort 4a (Niraparib, Irinotecan)Experimental

Participants weighing \< 77 kg will receive a starting dose of 200 mg of niraparib on days 1-7 each 21-day cycle, and 150 mg/m\^2 of irinotecan on day 1 of each 21 day cycle until unacceptable toxicity, disease progression or participant withdrawal.

Cohort 4b (Niraparib, Irinotecan)Experimental

Participants weighing \>= 77 kg will receive a starting dose of 300 mg of niraparib on days 1-7 each 21-day cycle, and 150 mg/m\^2 of irinotecan on day 1 of each 21 day cycle until unacceptable toxicity, disease progression or participant withdrawal.

Drugs: Niraparib, Irinotecan

Sites

1 site in 1 country

  • University of California, San FranciscoSan Francisco, California, United States